V116 has the broadest coverage, but we’ll have to wait for the immunogenicity data to know if it’s as effective as Prevnar-20 against the shared serotypes.
Note that V116, in contrast to Prevar-20 and Vaxneuvance, is intended for the adult market only.
MRK’s V116 shows non-inferiority to Prevnar-20 in two phase-3 trials (one for pneumococcal-vaccine naïve patients and one for patients who received a prior pneumococcal vaccine):
V116 is a 21-valent pneumococcal vaccine intended for the adult market only. PFE’s Prevnar-20 currently owns virtually the entire adult market for pneumococcal vaccines because CDC/ACIP’s recommendations give preferential treatment to Prevnar-20 vs MRK’s 15-valent V114 (a/k/a Vaxneuvance) (#msg-166441188).
The V116 results announced today put MRK back in the ballgame for the adult segment of the market.
News 
Market Data 
Discover 
